Please ensure Javascript is enabled for purposes of website accessibility

CDC Advises Americans to Postpone Cruises

By Prosper Junior Bakiny - Updated Mar 9, 2020 at 5:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The elderly and people with underlying health issues are at particular risk.

With the coronavirus epidemic spreading, the Centers for Disease Control is recommending that people avoid cruise ship travel for now. The warning is particularly aimed at older people and those with chronic health conditions such as heart disease and diabetes, as they seem to be at higher risk of experiencing severe cases of COVID-19 if they contract it.

SARS-CoV-2, the coronavirus that causes COVID-19, is thought to spread primarily from person to person, which means large gatherings of individuals in closed quarters -- which are natural features of cruises -- create ideal conditions for it to spread.

Passengers and crew aboard the Grand Princess have been stuck on that vessel for days off the coast of San Francisco. As of March 6, 21 people on the cruise ship had tested positive for COVID-19 -- 19 crew members and two guests. Authorities are to begin what they expect to be a multiday process of disembarking the more than 2,400 passengers Monday. All will face another 2 weeks of quarantine

Nurse holding test tube with blood for Coronavirus testing

Image Source: Getty Images.

The race to prevent a COVID-19 pandemic continues

There are now more than 500 confirmed cases of the potentially deadly disease in the U.S. across more than two dozen states. Several biotechnology companies are currently racing to find a treatment or a vaccine for COVID-19. This list includes Gilead Sciences (GILD -1.07%), which recently initiated two phase 3 clinical trials investigating the efficacy of its antiviral product -- remdesivir -- as a treatment for COVID-19.

One of the trials will involve 400 patients with "severe clinical manifestations" of COVID-19, and the other will enroll 600 patients with moderate manifestations of the disease.

In each trial, patients will be given daily oral doses of remdesivir for five or 10 days. Remdesivir was originally developed as a treatment for Ebola, but it showed little success against that disease.

Other companies such as Inovio Pharmaceuticals (INO -3.35%) and Novavax (NVAX -0.81%) have developed potential vaccines for COVID-19; however, neither has started clinical trials of their candidates yet.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$61.81 (-1.07%) $0.67
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$51.43 (-0.81%) $0.42
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.73 (-3.35%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.